AEON Biopharma Files 8-K
Ticker: AEON · Form: 8-K · Filed: Jan 6, 2025 · CIK: 1837607
Sentiment: neutral
Topics: disclosure, financials, corporate-action
TL;DR
AEON Biopharma filed an 8-K on Jan 6, 2025, covering Reg FD and financials. Formerly Priveterra Acquisition Corp.
AI Summary
AEON Biopharma, Inc. filed an 8-K on January 6, 2025, reporting on a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as Priveterra Acquisition Corp., is incorporated in Delaware and headquartered in Irvine, California.
Why It Matters
This filing provides an update on AEON Biopharma's regulatory disclosures and financial reporting, which is crucial for investors to understand the company's current status and compliance.
Risk Assessment
Risk Level: low — This is a routine filing of an 8-K, indicating standard disclosure practices rather than a specific event that would inherently increase risk.
Key Players & Entities
- AEON Biopharma, Inc. (company) — Registrant
- Priveterra Acquisition Corp. (company) — Former company name
- January 6, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Irvine, CA (location) — Principal executive offices
FAQ
What specific Regulation FD Disclosure is being made by AEON Biopharma, Inc. in this 8-K?
The filing indicates a Regulation FD Disclosure, but the specific details of this disclosure are not provided in the provided text excerpt.
What are the key financial statements and exhibits included in this 8-K filing?
The filing states that Financial Statements and Exhibits are included, but the specific content of these documents is not detailed in the excerpt.
When did AEON Biopharma, Inc. change its name from Priveterra Acquisition Corp.?
The date of the name change from Priveterra Acquisition Corp. to AEON Biopharma, Inc. was December 22, 2020.
What is the principal executive office address for AEON Biopharma, Inc.?
The principal executive offices are located at 5 Park Plaza, Suite 1750, Irvine, CA 92614.
What is the IRS Employer Identification Number for AEON Biopharma, Inc.?
The IRS Employer Identification Number for AEON Biopharma, Inc. is 85-3940478.
Filing Stats: 401 words · 2 min read · ~1 pages · Grade level 11.7 · Accepted 2025-01-06 09:00:55
Key Financial Figures
- $0.0001 — hich registered Class A Common Stock, $0.0001 par value per share AEON NYSE Ameri
Filing Documents
- tm2432042d2_8k.htm (8-K) — 28KB
- tm2432042d2_ex99-1.htm (EX-99.1) — 17KB
- tm2432042d2_ex99-1img001.jpg (GRAPHIC) — 2KB
- 0001104659-25-001109.txt ( ) — 226KB
- aeon-20250106.xsd (EX-101.SCH) — 3KB
- aeon-20250106_lab.xml (EX-101.LAB) — 33KB
- aeon-20250106_pre.xml (EX-101.PRE) — 22KB
- tm2432042d2_8k_htm.xml (XML) — 4KB
01 Regulation FD
Item 7.01 Regulation FD Disclosure On January 6, 2025, AEON Biopharma, Inc. (the "Company") issued a press release. A copy of the press release is furnished hereto as Exhibit 99.1 and incorporated herein by reference. Exhibits 9.01 Financial Exhibit No. Description 99.1 Pricing Press Release, dated January 6, 2025 104 Cover Page Interactive Data File (embedded with the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AEON Biopharma, Inc. Date: January 6, 2025 By: /s/ Marc Forth Marc Forth Chief Executive Officer